P/E at 30.07 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 30.07, which is approximately 18.8% lower than the Pharmaceuticals & Biotechnology industry average of 37.05. This discount suggests that the market is pricing in either a relative undervaluation or concerns about the company’s near-term earnings growth compared to its peers. Given the sector’s elevated valuation, this gap is significant and invites scrutiny of the underlying fundamentals and market sentiment. Dr Reddys Laboratories Ltd’s mid-cap status with a market capitalisation of ₹96,756.10 crores places it in a competitive position within the sector, yet the valuation gap remains a key point of interest for analysts and investors alike.

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns reveals a complex performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 10.89%, underperforming the Sensex’s 8.11% fall. This underperformance extends to the three-month period, where the stock dropped 9.38%, significantly worse than the Sensex’s 1.46% decline. However, the one-month return of -3.56% closely tracks the Sensex’s -3.66%, and the one-week performance shows a modest gain of 0.67% compared to the Sensex’s 0.56% loss. This recent short-term resilience is further underscored by a two-day consecutive gain, during which the stock rose 2.2%, despite a slight dip of 0.16% on the latest trading day.

This divergence between medium-term weakness and short-term recovery raises questions about the sustainability of the recent momentum — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The data suggests investors are cautiously optimistic in the near term, but the broader downtrend remains a concern.

Moving Average Configuration: Signs of a Partial Bounce

The technical setup of Dr Reddys Laboratories Ltd offers further insight into its price action. The stock currently trades above its 5-day moving average but remains below the 20-day, 50-day, 100-day, and 200-day moving averages. This configuration indicates a short-term bounce within a longer-term downtrend. The fact that the stock has not yet breached the longer-term averages suggests that the recovery is tentative and may face resistance ahead. Such a pattern often reflects investor uncertainty, where short-term optimism is tempered by caution over the broader trend.

Relative Performance Versus Sensex

Over longer horizons, Dr Reddys Laboratories Ltd has struggled to keep pace with the broader market. Its three-year return is -0.46%, compared to the Sensex’s 10.78% gain. The five-year return of 16.74% also lags behind the Sensex’s 27.98%, while the ten-year return of 84.49% is roughly half the Sensex’s 164.50%. These figures highlight a persistent underperformance trend over multiple timeframes, despite the company’s strong sector presence. The year-to-date return of -8.80% is somewhat better than the Sensex’s -11.82%, indicating a relative improvement in 2026, though the stock remains in negative territory.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 negative. This distribution suggests a sector grappling with uneven performance, where Dr Reddys Laboratories Ltd’s challenges are not isolated but part of a broader industry dynamic. The stock’s valuation discount relative to the sector average may reflect these sector-wide headwinds as well as company-specific factors.

Rating Reassessment: Previously Hold, Now Updated

On 13 July 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold, as per MarketsMOJO’s previous assessment. The current Mojo Score stands at 30.0, with a Mojo Grade of Sell. This change reflects a reassessment of the company’s fundamentals, valuation, and technical indicators. The rating update invites investors to consider the implications of the valuation discount and the mixed performance signals — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Conclusion: A Complex Valuation and Performance Landscape

The data on Dr Reddys Laboratories Ltd reveals a stock trading at a meaningful discount to its sector peers, with a P/E ratio 18.8% below the industry average. Despite this valuation gap, the stock’s performance has been mixed, with medium-term underperformance contrasting with recent short-term gains and a tentative technical bounce. The moving average configuration underscores this uncertainty, showing recovery signs that have yet to overcome longer-term resistance levels.

Sector results are varied, reflecting broader challenges in Pharmaceuticals & Biotechnology, which may be influencing the stock’s valuation and momentum. The recent rating reassessment from Hold to a different grade signals a shift in the evaluation of the company’s prospects, factoring in these complex dynamics — what is the current rating for Dr Reddys Laboratories Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →